Effects of IND/GLY on PROs in men and women compared with other comparators at Week 26
| Parameters | IND/GLY vs SFC | IND/GLY vs GLY | IND/GLY vs TIO | IND/GLY vs PBO | ||||
|---|---|---|---|---|---|---|---|---|
| Men | Women | Men | Women | Men | Women | Men | Women | |
| TDI total scores | 0.46 (0.06, 0.85)* | 0.65 (−0.12, 1.43) | 0.23 (−0.23, 0.68) | 1.31 (0.52, 2.10)† | 0.51 (0.05, 0.97)* | 1.39 (0.63, 2.15)‡ | 0.66 (0.05, 1.26)* | 2.51 (1.52, 3.51)τ |
| SGRQ total scores | −0.93 (−2.53, 0.66) | −1.93 (−4.92, 1.06) | −1.36 (−2.57, −0.14)* | −2.83 (−4.91, −0.75)† | −2.51 (−3.72, −1.31)τ | −1.83 (−3.90, 0.24) | −2.27 (−4.59, 0.06) | −6.82 (−10.6, −3.01)‡ |
| Symptom scores (total) via e-diary | −0.37 (−0.82, 0.09) | 0.06 (−0.60, 0.73) | −0.34 (−0.60, −0.08)† | −0.40 (−0.82, 0.02) | −0.39 (−0.65, −0.13)† | −0.62 (−1.05, −0.19)† | −0.22 (−0.79, 0.35) | −0.31 (−1.30, 0.68) |
| Rescue medication use | −0.14 (−0.45, 0.17) | −0.03 (−0.74, 0.67) | −0.66 (−0.89, −0.43)τ | −1.22 (−1.66, −0.78)τ | −0.53 (−0.76, −0.30)τ | −1.13 (−1.56, −0.69)τ | −0.66 (−1.03, −0.29)‡ | −1.12 (−1.84, −0.40)† |
pp < 0.05; †p < 0.01; ‡p < 0.001; τp < 0.0001; data presented as LSM (95% confidence interval); e-diary, electronic diary; IND/GLY, indacaterol/glycopyrronium (110/50 µg once daily); LSM, least square mean; PBO, placebo; PRO, patient-reported outcome; SFC, salmeterol/fluticasone (50/500 µg twice daily); SGRQ, St. George’s Respiratory Questionnaire; TDI, transition dyspnoea index; TIO, tiotropium (18 µg once daily)